US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

DAMORA THERAPEUT

28.18

-0.8200-2.83%

Post-market: 28.180.00000.00%19:30 EDT

Volume:497.02K

Turnover:13.89M

Market Cap:1.73B

PE:-2.85

High:28.93

Open:28.93

Low:26.53

Close:29.00

52wk High:38.33

52wk Low:2.45

Shares:61.55M

Float Shares:47.65M

Volume Ratio:1.98

T/O Rate:1.04%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-9.8764

EPS(LYR):-153.9532

ROE:-99.74%

ROA:-21.61%

PB:4.49

PE(LYR):-0.18

Loading ...

Overview Company News Filings

BRIEF-Damora Therapeutics Reports First Quarter 2026 Financial Results

Damora Therapeutics posts corporate deck on mutCALR-targeted therapies for MPN blood cancers

Damora Therapeutics: Q1 EPS $-0.62

THOMSON REUTERS

Damora Therapeutics Inc - on Track for First Regulatory Submission for Dmr-001 in Mid-2026

THOMSON REUTERS

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Damora net loss widens to $27.78 million in Q1 2026

Damora Therapeutics SVP Finance Brian Burkavage files initial beneficial ownership statement

A Look At Damora Therapeutics (DMRA) Valuation After Recent Share Price Momentum And Negative Equity Signals

Simply Wall St.

BRIEF-Damora Therapeutics: Lori Firmani To Cease Serving As CFO Effective May 1, 2026 - SEC Filing

Damora Therapeutics Inc - Lori Firmani to Cease Serving as CFO Effective May 1, 2026 - SEC Filing

THOMSON REUTERS

Damora Therapeutics names Brian Burkavage principal financial officer, accounting officer

Damora Therapeutics grants options for 57,500 shares at $25.66 under inducement plan

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Guggenheim Reaffirms Their Buy Rating on Damora Therapeutics (DMRA)

Damora Faces Upside As Fast-Follower CALR 'Should Make Bigger Splash,' RBC Says

MT Newswires Live

Damora Therapeutics replaces EY Denmark with EY US as auditor

Is Damora Therapeutics’ (DMRA) New CEO and Fast Track Status Reframing Its Pipeline Execution Story?

Simply Wall St.

Damora Therapeutics files Form 3 for CEO, Director Jennifer Jarrett

Damora grants CEO Jennifer Jarrett 1.5 million stock options, 500,000 RSUs as inducement award

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/DMRA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DMRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DMRA\",,,,,undefined,":{"symbol":"DMRA","market":"US","secType":"STK","nameCN":"DAMORA THERAPEUT","latestPrice":28.18,"timestamp":1788206400000,"preClose":29,"halted":0,"volume":497024,"hourTrading":{"tag":"盘后","latestPrice":28.18,"preClose":28.18,"latestTime":"19:30 EDT","volume":61701,"amount":1738725.851362,"timestamp":1788219002395,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.028275862068965527,"floatShares":47648701,"shares":61553200,"eps":-9.876431,"marketStatus":"Not Yet Opened","change":-0.82,"latestTime":"08-31 16:00:00 EDT","open":28.93,"high":28.93,"low":26.525,"amount":13892240.288256,"amplitude":0.082931,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-9.876431,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788249600000},"marketStatusCode":0,"adr":0,"listingDate":1603944000000,"exchange":"NASDAQ","adjPreClose":29,"preHourTrading":{"tag":"盘前","latestPrice":28.88,"preClose":29,"latestTime":"09:29 EDT","volume":373,"amount":10777.15987,"timestamp":1788182999999,"change":-0.12,"changeRate":-0.004138,"amplitude":0.026552},"postHourTrading":{"tag":"盘后","latestPrice":28.18,"preClose":28.18,"latestTime":"19:30 EDT","volume":61701,"amount":1738725.851362,"timestamp":1788219002395,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.981107},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DMRA\",,,,,undefined,":{"symbol":"DMRA","floatShares":47648701,"roa":"-21.61%","roe":"-99.74%","lyrEps":-153.953213,"volumeRatio":1.981107,"shares":61553200,"dividePrice":0,"high":28.93,"amplitude":0.082931,"preClose":29,"low":26.525,"week52Low":2.45,"pbRate":"4.49","week52High":38.3251,"institutionHeld":0,"latestPrice":28.18,"eps":-9.876431,"divideRate":0,"volume":497024,"delay":0,"ttmEps":-9.876431,"open":28.93,"prevYearClose":23.01,"prevWeekClose":29,"prevMonthClose":28.99,"prevQuarterClose":26.01,"fiveDayClose":30.31,"twentyDayClose":28.56,"sixtyDayClose":22.31},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DMRA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-12","symbol":"DMRA","fiscalQuarterEnding":"2026/03","expectedEps":-0.21,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.62},{"market":"US","date":"2026-03-19","symbol":"DMRA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773892800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-06","symbol":"DMRA","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-2.36},{"market":"US","date":"2025-08-05","symbol":"DMRA","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"post","actualEps":-2.6},{"market":"US","date":"2025-05-08","symbol":"DMRA","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-1.92}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DMRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DMRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":10,"updateTime":1785297600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DMRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DMRA","date":"2026-08-28","current":-2.853257,"percent":0.538462,"low":-100.260711,"twenty":-7.738833,"median":-7.209243,"eighty":-6.354091,"high":-5.207587,"avg":-12.775313,"sd":21.566701,"marketCap":1889106881},"quantilePoints":[{"date":"2026-03-13","current":-100.260711,"twenty":-100.260711,"median":-100.260711,"eighty":-98.29884,"marketCap":1588530698},{"date":"2026-03-20","current":-72.999835,"twenty":-100.199878,"median":-95.983376,"eighty":-84.763454,"marketCap":1156609382},{"date":"2026-03-27","current":-7.36551,"twenty":-98.861547,"median":-80.41388,"eighty":-7.003988,"marketCap":1545571323},{"date":"2026-04-02","current":-7.207452,"twenty":-96.587906,"median":-7.443103,"eighty":-7.019507,"marketCap":1512404556},{"date":"2026-04-10","current":-7.670132,"twenty":-94.238224,"median":-7.361199,"eighty":-7.021806,"marketCap":1609492728},{"date":"2026-04-17","current":-7.759219,"twenty":-89.113027,"median":-7.443103,"eighty":-7.088477,"marketCap":1628186724},{"date":"2026-04-24","current":-7.305161,"twenty":-78.931071,"median":-7.519258,"eighty":-7.200555,"marketCap":1532907649},{"date":"2026-05-01","current":-7.374132,"twenty":-59.951712,"median":-7.420112,"eighty":-7.071235,"marketCap":1547380419},{"date":"2026-05-08","current":-7.181588,"twenty":-7.748873,"median":-7.369821,"eighty":-7.098823,"marketCap":1506977267},{"date":"2026-05-15","current":-6.125513,"twenty":-7.702318,"median":-7.328151,"eighty":-6.979849,"marketCap":1440040702},{"date":"2026-05-22","current":-6.376895,"twenty":-7.679328,"median":-7.296539,"eighty":-6.874668,"marketCap":1499137850},{"date":"2026-05-29","current":-6.50384,"twenty":-7.670132,"median":-7.208889,"eighty":-6.624282,"marketCap":1528981338},{"date":"2026-06-05","current":-5.841412,"twenty":-7.647141,"median":-7.181588,"eighty":-6.506459,"marketCap":1373251758},{"date":"2026-06-12","current":-5.592674,"twenty":-7.644267,"median":-7.103996,"eighty":-6.310202,"marketCap":1314776223},{"date":"2026-06-18","current":-5.608384,"twenty":-7.605184,"median":-7.036462,"eighty":-6.158347,"marketCap":1318469415},{"date":"2026-06-26","current":-5.909488,"twenty":-7.595413,"median":-6.974676,"eighty":-5.98699,"marketCap":1389255588},{"date":"2026-07-02","current":-7.092956,"twenty":-7.5092,"median":-6.96318,"eighty":-6.007936,"marketCap":1667476025},{"date":"2026-07-10","current":-8.059107,"twenty":-7.645417,"median":-7.006288,"eighty":-6.078901,"marketCap":1894607311},{"date":"2026-07-17","current":-7.917719,"twenty":-7.67473,"median":-7.092956,"eighty":-6.150138,"marketCap":1861368586},{"date":"2026-07-24","current":-7.637561,"twenty":-7.776537,"median":-7.12986,"eighty":-6.183485,"marketCap":1795506668},{"date":"2026-07-31","current":-7.648035,"twenty":-7.738833,"median":-7.190209,"eighty":-6.195797,"marketCap":1797968796},{"date":"2026-08-07","current":-7.82346,"twenty":-7.815082,"median":-7.208161,"eighty":-6.219919,"marketCap":1839209436},{"date":"2026-08-14","current":-7.218207,"twenty":-7.815082,"median":-7.209243,"eighty":-6.276357,"marketCap":1897132498},{"date":"2026-08-21","current":-7.119553,"twenty":-7.785196,"median":-7.218207,"eighty":-6.321676,"marketCap":1871203580},{"date":"2026-08-28","current":-7.187671,"twenty":-7.738833,"median":-7.209243,"eighty":-6.354091,"marketCap":1889106881}],"updateTime":1788241326548},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DMRA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635256302","title":"BRIEF-Damora Therapeutics Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635256302","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635256302?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:43","pubTimestamp":1778622212,"startTime":"0","endTime":"0","summary":"BRIEF-Damora Therapeutics Reports First Quarter 2026 Financial Results May 12 (Reuters) - Damora Therapeutics Inc DMRA.O:DAMORA THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND RECENT COR","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA7M5BJF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635240961","title":"Damora Therapeutics posts corporate deck on mutCALR-targeted therapies for MPN blood cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2635240961","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635240961?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:21","pubTimestamp":1778617298,"startTime":"0","endTime":"0","summary":"Damora outlined development plans for mutCALR-targeted antibody programs in myeloproliferative neoplasms, highlighting lead asset DMR-001 with first regulatory submission targeted for mid-2026.DMR-001 described as Fc-null, extended half-life antibody designed to block mutCALR-driven signaling without immune effector engagement, with subcutaneous dosing planned at every 4 weeks or longer using an autoinjector.Pipeline timeline also showed DMR-002, an Fc-enhanced anti-mutCALR antibody with first regulatory submission expected in 2H 2026, alongside DMR-003, a mutCALR x CD3 T-cell engager with first regulatory submission expected in 2027.Presentation cited about $533 million in cash to advance DMR-001 through proof-of-concept into registrational development.Market sizing in mutCALR-driven essential thrombocythemia and myelofibrosis estimated at more than $5 billion in total addressable market in US, with about 42,000 prevalent mutCALR-driven MPN patients.Disclaimer: This news brief was cre","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL21rXFD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635225562","title":"Damora Therapeutics: Q1 EPS $-0.62","url":"https://stock-news.laohu8.com/highlight/detail?id=2635225562","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635225562?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616304,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA7M5BJF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635225537","title":"Damora Therapeutics Inc - on Track for First Regulatory Submission for Dmr-001 in Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635225537","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635225537?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616304,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA7M5BJF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635424063","title":"Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2635424063","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635424063?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616300,"startTime":"0","endTime":"0","summary":"– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress – – On track to submit fir","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3293403/0/en/Damora-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Recent-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4226","BK4561","ET","DMRA","BK4581","BK4539","BK4144","BK4585","XELA","BK4139","BK4590","BK4007","BK4106","LENZ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635724203","title":"Damora net loss widens to $27.78 million in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635724203","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635724203?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:03","pubTimestamp":1778616184,"startTime":"0","endTime":"0","summary":"Damora Therapeutics posted a net loss of $27.78 million, swinging from a net loss of $2.53 million a year earlier.Operating loss widened to $30.81 million from $2.6 million, as total operating expenses climbed to $30.81 million from $2.6 million.Research and development costs jumped to $23.78 million from $678,000, including $17 million tied to services provided by Paragon under the Paragon Option Agreement.General and administrative expense rose to $7.03 million from $1.92 million, while other income increased to $3.07 million from $68,000 on higher interest income following recent financings.Cash and cash equivalents totaled $532.9 million as of March 31, 2026; Damora said it expects existing cash to fund operations into 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDLbJKP6M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634467373","title":"Damora Therapeutics SVP Finance Brian Burkavage files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2634467373","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634467373?lang=en_us&edition=fundamental","pubTime":"2026-05-09 05:01","pubTimestamp":1778274065,"startTime":"0","endTime":"0","summary":"Damora Therapeutics SVP, Finance Brian Burkavage reported a stock option covering 312,535 common shares at USD 32, expiring Dec. 15, 2035.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDLb8RNMf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633291900","title":"A Look At Damora Therapeutics (DMRA) Valuation After Recent Share Price Momentum And Negative Equity Signals","url":"https://stock-news.laohu8.com/highlight/detail?id=2633291900","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633291900?lang=en_us&edition=fundamental","pubTime":"2026-05-05 18:20","pubTimestamp":1777976448,"startTime":"0","endTime":"0","summary":"Damora Therapeutics stock snapshot\nDamora Therapeutics (DMRA) has drawn investor attention after recent share price moves, with the stock closing at US$25.93 and showing mixed return patterns across the past week, month, past 3 months and year to date.\nSee our latest analysis for Damora Therapeutics.\nThe recent 1-day and 30-day share price returns of 2.25% and 3.35% respectively come on top of an 18.84% year to date share price return. The 1-year total shareholder return is around 7.5x, set...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dmra/damora-therapeutics/news/a-look-at-damora-therapeutics-dmra-valuation-after-recent-sh","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dmra/damora-therapeutics/news/a-look-at-damora-therapeutics-dmra-valuation-after-recent-sh","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LENZ","BK4539","BK4215","BK4588","EQR","DMRA","BK4139","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633966202","title":"BRIEF-Damora Therapeutics: Lori Firmani To Cease Serving As CFO Effective May 1, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2633966202","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633966202?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:31","pubTimestamp":1777926696,"startTime":"0","endTime":"0","summary":"BRIEF-Damora Therapeutics: Lori Firmani To Cease Serving As CFO Effective May 1, 2026 - SEC FilingMay 4  - Damora Therapeutics Inc DMRA.O:DAMORA THERAPEUTICS INC - LORI FIRMANI TO CEASE SERVING AS CFO EFFECTIVE MAY 1, 2026 - SEC FILINGDAMORA THERAPEUTICS INC - APPOINTS BRIAN BURKAVAGE AS PRINCIPAL FINANCIAL OFFICER EFFECTIVE MAY 1, 2026 - SEC FILINGSource text: [ID:n0001193125-26-203913]Further company coverage: DMRA.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nFWN41H0WO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633665929","title":"Damora Therapeutics Inc - Lori Firmani to Cease Serving as CFO Effective May 1, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2633665929","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633665929?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:21","pubTimestamp":1777926071,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nFWN41H0WO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633963927","title":"Damora Therapeutics names Brian Burkavage principal financial officer, accounting officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2633963927","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633963927?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:01","pubTimestamp":1777924862,"startTime":"0","endTime":"0","summary":"Damora Therapeutics set May 1, 2026 as effective date for CFO Lori Firmani to step down.Senior Vice President, Finance Brian Burkavage will become principal financial officer and principal accounting officer at that time.Burkavage previously served as senior vice president, finance and chief accounting officer at IO Biotech from November 2021 to December 2025.Earlier roles included controller at Passage Bio, director of financial planning and analysis at Aclaris Therapeutics, and 11 years at Ernst & Young in audit.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDLbYN4kT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMRA","BK4139","BK4007","PASG","ACRS","IOBTQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632614801","title":"Damora Therapeutics grants options for 57,500 shares at $25.66 under inducement plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2632614801","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632614801?lang=en_us&edition=fundamental","pubTime":"2026-05-01 20:03","pubTimestamp":1777637005,"startTime":"0","endTime":"0","summary":"Damora Therapeutics granted non-qualified stock options covering 57,500 shares to two newly hired, non-executive employees.Options carry a 10-year term with an exercise price of $25.66 per share.Vesting schedules 25% on first anniversary of grant date.Remaining options vest in equal monthly installments over following 36 months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief on May 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL1wBsjv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632614675","title":"Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2632614675","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632614675?lang=en_us&edition=fundamental","pubTime":"2026-05-01 20:00","pubTimestamp":1777636800,"startTime":"0","endTime":"0","summary":"BOSTON, May  01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/01/3285886/0/en/Damora-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","LENZ","DMRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631515581","title":"Guggenheim Reaffirms Their Buy Rating on Damora Therapeutics (DMRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2631515581","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631515581?lang=en_us&edition=fundamental","pubTime":"2026-04-29 19:36","pubTimestamp":1777462578,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Bradley Canino maintained a Buy rating on Damora Therapeutics today and set a price target of $40.00. According to TipRanks, Can...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-reaffirms-their-buy-rating-on-damora-therapeutics-dmra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-reaffirms-their-buy-rating-on-damora-therapeutics-dmra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630038825","title":"Damora Faces Upside As Fast-Follower CALR 'Should Make Bigger Splash,' RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2630038825","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630038825?lang=en_us&edition=fundamental","pubTime":"2026-04-24 23:54","pubTimestamp":1777046084,"startTime":"0","endTime":"0","summary":"Damora Therapeutics (DMRA) is capitalizing on growing validation of using mutant calreticulin targeting therapies in myeloproliferative neoplasms, and may have the additional advantage of acharted reg","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DMRA","INCY","BK4585","BK4532","BK4550","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629541775","title":"Damora Therapeutics replaces EY Denmark with EY US as auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2629541775","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629541775?lang=en_us&edition=fundamental","pubTime":"2026-04-21 04:01","pubTimestamp":1776715266,"startTime":"0","endTime":"0","summary":"Audit reports for fiscal years ended Dec. 31, 2025 and 2024 carried no adverse opinion or disclaimer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDLbPW7GS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626711433","title":"Is Damora Therapeutics’ (DMRA) New CEO and Fast Track Status Reframing Its Pipeline Execution Story?","url":"https://stock-news.laohu8.com/highlight/detail?id=2626711433","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626711433?lang=en_us&edition=fundamental","pubTime":"2026-04-11 00:18","pubTimestamp":1775837883,"startTime":"0","endTime":"0","summary":"Earlier this week, Damora Therapeutics highlighted recent corporate developments, including the appointment of Jennifer Jarrett as President and CEO and an FDA fast track designation for its ovarian cancer therapy candidate.\nTogether, these changes spotlight how leadership decisions and regulatory milestones can reshape how investors think about a small biotech’s development pipeline and execution priorities.\nWe’ll now examine how the FDA fast track designation, in particular, could...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dmra/damora-therapeutics/news/is-damora-therapeutics-dmra-new-ceo-and-fast-track-status-re","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dmra/damora-therapeutics/news/is-damora-therapeutics-dmra-new-ceo-and-fast-track-status-re","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4007","LENZ","BK4539","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624010544","title":"Damora Therapeutics files Form 3 for CEO, Director Jennifer Jarrett","url":"https://stock-news.laohu8.com/highlight/detail?id=2624010544","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624010544?lang=en_us&edition=fundamental","pubTime":"2026-04-02 05:25","pubTimestamp":1775078721,"startTime":"0","endTime":"0","summary":"Damora Therapeutics filed a Form 3 initial beneficial ownership statement for Jennifer Jarrett, president, chief executive officer, director.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDLbtdbGs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623431795","title":"Damora grants CEO Jennifer Jarrett 1.5 million stock options, 500,000 RSUs as inducement award","url":"https://stock-news.laohu8.com/highlight/detail?id=2623431795","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623431795?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:12","pubTimestamp":1774872758,"startTime":"0","endTime":"0","summary":"Damora Therapeutics granted new-hire equity awards to President and CEO Jennifer Jarrett on March 30, 2026.Jarrett also received stock options for 1.5 million shares with exercise price $25.50 per share.Vesting terms set 25% of options after one year, then monthly over 36 months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief on March 30, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL8Mv0gX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623317849","title":"Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623317849","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623317849?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:00","pubTimestamp":1774872000,"startTime":"0","endTime":"0","summary":"BOSTON, March  30, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/30/3264550/0/en/Damora-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","BK4007","BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":72,"code":"91000000","status":"200"}]}}